Efficacy of Propafenone Versus Dronedarone for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation
Information source: Samsung Medical Center
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Atrial Fibrillation
Intervention: Propafenone (Drug); Dronedarone (Drug)
Phase: N/A
Status: Completed
Sponsored by: Samsung Medical Center Official(s) and/or principal investigator(s): Young Keun On, MD, PhD, Principal Investigator, Affiliation: Samsung Medical Center
Summary
the purpose of this study is to compare the ability of propafenone and dronedarone to
maintain sinus rhythm after DC cardioversion
Clinical Details
Official title: Efficacy of Propafenone Versus Dronedarone for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation After DC Cardioversion
Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: recurrence of atrial fibrillation
Detailed description:
Atrial fibrillation is the most common arrhythmia requiring continuous therapy. Conversion
to and maintenance of sinus rhythm is important. Propafenone and dronedarone has been used
as treatment for maintenance of sinus rhythm after DC cardioversion. But there are no direct
comparison study.
The purpose of this study is to compare the ability of propafenone and dronedarone to
maintain sinus rhythm after DC cardioversion.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- a patient with persistent atrial fibrillation who received successful DC
cardioversion
Exclusion Criteria:
- prior amiodarone use
- NYHA class III or IV heart failure
- Left ventricular ejection fraction < 35%
- second or third AV block
- sick sinus syndrome
- heart rate < 50 beat per minute
- myocardiac infarction within 3 months
- pregnant women
- severe hepatic dysfunction
- QT prolongation > 500ms or PR interval > 180ms
- history of hypersensitivity for drug
Locations and Contacts
Cardiac and Vascular Center, Seoul 135-710, Korea, Republic of
Additional Information
Starting date: May 2011
Last updated: November 17, 2013
|